Ira Winer, MD
Gynecologic Oncology · Detroit, MINPI 1790982031
Payments from drug & device makers
Across 1,402 payments — averaging $7009.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$3.7M
- Genmab U.S., Inc.$2.2M
- Regeneron$2.1M
- Merck$1.1M
- Exelixis Inc.$227K
- GSK$199K
- plus $389K from 19 others
Across 8 payments — averaging $233.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 359 | $3,655,600 |
| Genmab U.S., Inc. | 347 | $2,197,165 |
| Regeneron | 309 | $2,094,247 |
| Merck | 108 | $1,066,579 |
| Exelixis Inc. | 74 | $226,877 |
| GSK | 53 | $198,676 |
| Genmab A/s | 39 | $107,501 |
| Boehringer Ingelheim International GmbH | 19 | $91,900 |
| Theratechnologies Inc. | 14 | $50,791 |
| Immunogen, Inc. | 10 | $27,513 |
| AbbVie | 14 | $22,485 |
| Clovis Oncology, Inc. | 25 | $21,766 |
| Eli Lilly | 3 | $21,537 |
| Roche Products Limited | 7 | $21,400 |
| Beigene USA, Inc. | 5 | $8,722 |
| Daiichi Sankyo Inc. | 2 | $5,190 |
| Beone Medicines USA, Inc. | 4 | $3,830 |
| Roche Diagnostics Corporation | 1 | $2,900 |
| AstraZeneca | 2 | $2,754 |
| Boehringer Ingelheim | 2 | $263 |
| Tesaro, Inc. | 1 | $27 |
| Johnson & Johnson | 1 | $19 |
| Fortovia Therapeutics, Inc. | 1 | $18 |
| Myriad Genetic Laboratories, Inc. | 1 | $18 |
| Novartis | 1 | $15 |
How this compares
$9,827,793 in reported general payments places this provider in the 95th percentile of 43 gynecologic oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Detroit
- Robert MorrisDetroit$2.9M
- Radhika GogoiDetroit$297K
- Morgan TaylorDetroit$23K
- Ahmad AwadaDetroit$5K
- Elizabeth JohnsDetroit$4K
- Kaitlin BurchettDetroit$3K
- Leigh SolomonDetroit$1K
- Sharif SakrDetroit$894
- Alexander ParidonDetroit$749
- Miriana HijazDetroit$565
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.